glp 1 agonist vs sglt2 inhibitor inhibitors or GLP-1 receptor agonists as second-line therapy in | VHRM Cardiovascular benefits of SGLT2 inhibitors

Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial

Rondanelli M, Perna S, Riva A, Petrangolini G, Di Paolo E, Gasparri C

Some investigators have proposed that GLP-1RAs improve myocardial insulin sensitivity, enhance glucose oxidation rates, reduce fatty acid oxidation, and thereby optimize myocardial energy metabolism, ultimately improving cardiac function.106 In a randomized controlled trial (RCT) conducted by Mikhail et al,106 semaglutide efficacy was evaluated in 616 patients with obesity-related heart failure and T2DM

The profound influence of GLP-1 receptor agonists on cardiovascular outcomes has been elucidated through a series of CVOTs

Consent for Publication Not applicable

Weighing risks and benefits of liraglutidethe FDA's review of a new antidiabetic therapy